Physician profile
Mitchell S Shek
NPI 1235129982
$5,916.89
in general payments reported to CMS, 2019-2025
37 companies · $838 in 2025
The $838 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,381 · 2020: $518 · 2021: $698 · 2022: $658 · 2023: $994 · 2024: $828 · 2025: $838.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,581 · Education: $79.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,581.08 |
| Education | $79.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $991.10 | 2019-2025 | Rinvoq |
| Galderma Laboratories, L.P. | $708.62 | 2019-2024 | Aklief, Oracea, Epsolay |
| Janssen Biotech, INC. | $569.27 | 2019-2025 | Tremfya, Stelara, Simponi Aria |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $383.72 | 2019-2024 | Arazlo, Cabtreo, Duobrii |
| Regeneron Healthcare Solutions, INC. | $312.29 | 2019-2025 | Dupixent |
| Sun Pharmaceutical Industries INC. | $267.45 | 2019-2025 | Absorica Ld, Winlevi |
| Pfizer INC. | $258.42 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $252.12 | 2019-2025 | |
| Epi Health, LLC | $224.30 | 2019-2022 | |
| Genzyme Corporation | $217.13 | 2019-2023 | |
| Leo Pharma INC. | $211.98 | 2022-2025 | Adbry |
| Dermavant Sciences, INC. | $198.24 | 2023-2024 | Vtama |
| Lilly USA, LLC | $187.35 | 2022-2024 | Taltz, Olumiant, Ebglyss |
| Ucb, INC. | $137.21 | 2022-2025 | Bimzelx |
| Almirall LLC | $103.98 | 2019-2023 | Seysara |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vyne Pharmaceuticals INC. | $96.39 | 2020-2021 | |
| Incyte Corporation | $89.80 | 2021-2025 | Opzelura |
| Merz North America, INC. | $88.79 | 2023 | |
| Organon LLC | $83.01 | 2025 | Vtama |
| Genentech USA, INC. | $81.95 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $59.66 | 2023-2024 | Sotyktu |
| Encore Dermatology INC. | $57.95 | 2019 | |
| Mayne Pharma Commercial LLC | $43.06 | 2022 | |
| Organogenesis INC. | $42.88 | 2024 | Affinity |
| Arcutis Biotherapeutics, INC. | $34.08 | 2023-2025 | Zoryve |
| Journey Medical Corporation | $24.12 | 2025 | |
| Melinta Therapeutics, LLC | $24.00 | 2019 | |
| Revance Therapeutics, INC. | $22.85 | 2024 | Daxxify |
| Solta Medical, A Division of Bausch Health US, LLC | $21.75 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $20.12 | 2024 | Spevigo |
| Verrica Pharmaceuticals INC. | $19.14 | 2023 | Ycanth |
| Dusa Pharmaceuticals, INC. | $16.99 | 2019 | |
| Medline Industries Lp | $14.69 | 2025 | |
| Lnhc, INC | $14.42 | 2025 | Zelsuvmi |
| Dermira, INC. | $13.33 | 2019 | |
| Paratek Pharmaceuticals, INC. | $13.22 | 2021 | |
| Sebela Pharmaceuticals INC. | $11.51 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mitchell Shek listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.